-
1 Comment
Deinove SA is currently in a long term downtrend where the price is trading 22.7% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.7.
Finally, its free cash flow grew by 44.4% to $-665K since the same quarter in the previous year.
Based on the above factors, Deinove SA gets an overall score of 2/5.
ISIN | FR0010879056 |
---|---|
Industry | Biotechnology |
Sector | Healthcare |
CurrencyCode | EUR |
Exchange | PA |
Beta | 0.79 |
---|---|
PE Ratio | None |
Market Cap | 1M |
Dividend Yield | 0.0% |
Target Price | 0.6 |
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. The company's pipeline includes DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers Dual-Acting Small Molecule Antibiotics, a class of dual activity antibiotics that develops a new class of 2-in-1 molecules whose structure results from the combination of two active antibiotic moieties. The company was founded in 2006 and is based in Grabels, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALDEI.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024